GlassScriptPhysician profile
Guillermo A Latiff
NPI 1780656843
$2,005.13
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $11.41 · 2021: $199 · 2022: $715 · 2023: $642 · 2024: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $783.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $449.80 | 2019-2023 | Erleada |
| Axonics, INC. | $376.86 | 2021-2024 | Axonics, Bulkamid |
| Antares Pharma, INC. | $145.89 | 2021-2022 | |
| Progenics Pharmaceuticals, INC. | $119.94 | 2022 | |
| Uroviu Corporation | $110.39 | 2023 | Uro-G Flexible Cystoscope |
| Coloplast Corp | $103.48 | 2022 | |
| Boston Scientific Corporation | $101.68 | 2019-2024 | Rezum Generator |
| Laborie Medical Technologies Corp. | $95.51 | 2023 | |
| Amgen INC. | $63.83 | 2019-2022 | |
| Calyxo, INC. | $54.86 | 2023 | Cvac Aspiration System |
| Urovant Sciences INC | $53.34 | 2021-2022 | |
| Caldera Medical, INC | $50.71 | 2023 | Desara |
| Alnylam Pharmaceuticals INC. | $36.55 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.28 | 2019-2022 | |
| Blue Earth Diagnostics | $31.79 | 2021-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $31.41 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $23.22 | 2022 | |
| Abbvie INC. | $22.41 | 2024 | |
| Dendreon Pharmaceuticals LLC | $21.33 | 2019 | |
| Sumitomo Pharma America, INC. | $19.77 | 2023 | Orgovyx |
| Sun Pharmaceutical Industries INC. | $16.41 | 2022 | |
| Merck Sharp & Dohme LLC | $16.35 | 2024 | Keytruda |
| Tolmar Pharmaceuticals, INC. | $13.79 | 2019 | |
| Myovant Sciences INC. | $13.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guillermo Latiff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.